Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Radiotherapy is one of the most successful cancer therapies. Here the effect of irradiation on antigen presentation by MHC class I molecules was studied. Cell surface expression of MHC class I molecules was increased for many days in a radiation dose-dependent manner as a consequence of three responses. Initially, enhanced degradation of existing proteins occurred which resulted in an increased intracellular peptide pool. Subsequently, enhanced translation due to activation of the mammalian target of rapamycin pathway resulted in increased peptide production, antigen presentation, as well as cytotoxic T lymphocyte recognition of irradiated cells. In addition, novel proteins were made in response to gamma-irradiation, resulting in new peptides presented by MHC class I molecules, which were recognized by cytotoxic T cells. We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor tissue. Our findings indicate that directed radiotherapy can improve the efficacy of tumor immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“irradiation can also increase tumor antigenicity through enriching the pool of antigenic peptides”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reits et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“folding the HLA-A1 heavy chain with peptides CGI-51(206–215), MSH6(469–478), and F-box protein Fbl7(335–362) and human β2m as described (51).”
BackgroundDNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
Schubert, U., Antón, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., & Bennink, J. R. (2000) · Nature · doi:10.1038/35008096 · Cited by 1,536
Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags
Mann, M., & Wilm, M. (1994) · Analytical Chemistry · doi:10.1021/ac00096a002 · Cited by 1,468
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 3×
“This is probably not due only to up-regulation of MHC class I expression because mTOR activation will have more general eff ects on protein expression including up-regulation of Fas, ICAM-1 (38), and interferon expression (33, 34).”
Background
Research works printed but not linked: 5
- 2000, Oncology (Huntingt), 14, 741
- 1988, Nippon Igaku Hoshasen Gakkai Zasshi., 48, 1572
- 2000, Anticancer Res., 20, 3375
- 2002, Cancer Res., 62, 1462
- 1991, Cancer Res., 51, 3657
Cited by
Items 401–500 of 1,000
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy
Maggs, L., Sadagopan, A., Moghaddam, A. S., & Ferrone, S. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.07.006 · Cited by 80
Spigel, D. R., & Socinski, M. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318286cf88 · Cited by 79
Näsman, A., Andersson, E. K., Marklund, L., Tertipis, N., Hammarstedt‐Nordenvall, L., Attner, P., Nyberg, T., Masucci, G. V., Munck‐Wikland, E., Ramqvist, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077025 · Cited by 79
Wu, Q., Allouch, A., Martins, I., Brenner, C., Modjtahedi, N., Deutsch, É., & Perfettini, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00613 · Cited by 79
Kesarwani, P., Prabhu, A. H., Kant, S., Kumar, P., Graham, S. F., Buelow, K. L., Wilson, G. D., Miller, C. R., & Chinnaiyan, P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0041 · Cited by 79
Gunderson, A. J., Yamazaki, T., McCarty, K., Phillips, M., Alice, A., Bambina, S., Zebertavage, L., Friedman, D., Cottam, B., Newell, P., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0211117 · Cited by 70
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 79
Radiotherapy: Brightness and darkness in the era of immunotherapy
Zhai, D., An, D., Wan, C., & Yang, K. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101366 · Cited by 79
Harnessing the Microbiome to Enhance Cancer Immunotherapy
Nelson, M. H., Diven, M. A., Huff, L. W., & Paulos, C. M. (2015) · Journal of Immunology Research · doi:10.1155/2015/368736 · Cited by 79
Ardiani, A., Gameiro, S. R., Kwilas, A. R., Donahue, R. N., & Hodge, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.2429 · Cited by 78
Self-citationEkshyyan, O. Y., Rong, Y., Rong, X., Pattani, K. M., Abreo, F. W., Caldito, G. C., Chang, J. K. S., Ampil, F. L., Glass, J., & Nathan, C. O. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1184 · Cited by 78
Different regulation of MHC Class I antigen processing components in human tumors
Seliger, B. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910802482870 · Cited by 77
Hernández, Á., Juanes‐Velasco, P., Landeira‐Viñuela, A., Bareke, H., Montalvillo, E., Góngora, R., & Fuentes, M. (2021) · Cancers · doi:10.3390/cancers13112821 · Cited by 77
Gorchs, L., Hellevik, T., Bruun, J.-A., Camilio, K.-A., Al-Saad, S., Stuge, T.-B., & Martinez-Zubiaurre, I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00087 · Cited by 71
Iida, N., Nakamoto, Y., Baba, T., Nakagawa, H., Mizukoshi, E., Naito, M., Mukaida, N., & Kaneko, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0096 · Cited by 76
Particle radiotherapy in the era of radioimmunotherapy
Zhou, Z., Guan, B., Xia, H., Zheng, R., & Xu, B. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216268 · Cited by 75
The nature of self for T cells — a systems-level perspective
Granados, D. P., Laumont, C. M., Thibault, P., & Perreault, C. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.10.012 · Cited by 75
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
Hovhannisyan, L., Riether, C., Aebersold, D. M., Medová, M., & Zimmer, Y. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01775-1 · Cited by 74
Radiation-induced immune responses: mechanisms and therapeutic perspectives
Jeong, H., Bok, S., Hong, B.-J., Choi, H.-S., & Ahn, G. (2016) · Blood Research · doi:10.5045/br.2016.51.3.157 · Cited by 74
Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation
Ko, E. C., Benjamin, K. T., & Formenti, S. C. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.08.021 · Cited by 67
Radiation therapy and immunotherapy: Implications for a combined cancer treatment
Lévy, A., Chargari, C., Cheminant, M., Simon‐Tillaux, N., Bourgier, C., & Deutsch, É. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.09.001 · Cited by 73
Chakraborty, M., Wansley, E. K., Carrasquillo, J. A., Yu, S. G., Paik, C. H., Camphausen, K. A., Becker, M. D., Goeckeler, W. F., Schlom, J., & Hodge, J. W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0335 · Cited by 73
Self-citationUnlocking the Combination: Potentiation of Radiation-Induced Antitumor Responses with Immunotherapy
Wattenberg, M. M., Fahim, A., Ahmed, M. M., & Hodge, J. W. (2014) · Radiation Research · doi:10.1667/rr13374.1 · Cited by 73
Self-citationHarnessing the Potential of Radiation-Induced Immune Modulation for Cancer Therapy
Ahmed, M. M., Hodge, J. W., Guha, C., Bernhard, E. J., Vikram, B., & Coleman, C. N. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0141 · Cited by 73
Self-citationBell, R. B., Leidner, R. S., Crittenden, M. R., Curti, B. D., Feng, Z., Montler, R. D., Gough, M. J., Fox, B. A., Weinberg, A. D., & Urba, W. J. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.009 · Cited by 73
Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
Belderbos, R. A., Aerts, J. G. J. V., & Vroman, H. H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.03.007 · Cited by 73
Wang, J., Xu, Y., Rao, X., Zhang, R., Tang, J. P., Zhang, D., Jie, X., Zhu, K., Wang, X., Xu, Y., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.718 · Cited by 72
Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature
Sharma, A., Bode, B., Studer, G., Moch, H., Okoniewski, M. J., Knuth, A. K., von Boehmer, L., & van den Broek, M. F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0352 · Cited by 72
Xie, Y., Bai, O., Yuan, J., Chibbar, R., Slattery, K., Wei, Y., Deng, Y., & Xiang, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0496 · Cited by 73
Bekeschus, S., Rödder, K., Fregin, B., Otto, O., Lippert, M., Weltmann, K., Wende, K., Schmidt, A., & Gandhirajan, R. K. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4396467 · Cited by 72
Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors to Radiation Therapy
Blair, T. C., Bambina, S., Alice, A. F., Kramer, G. F., Medler, T. R., Baird, J. R., Broz, M. L., Tormoen, G. W., Troesch, V., Crittenden, M. R., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000194 · Cited by 73
Gao, Y., Zhang, N., Zeng, Z., Wu, Q., Jiang, X., Li, S., Sun, W., Zhang, J., Li, Y., Li, J., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.792 · Cited by 71
Zhou, M., Chen, M., Shi, B., Di, S., Sun, R., Jiang, H., & Li, Z. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.021 · Cited by 69
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance
Zheng, W., Skowron, K. B., Namm, J. P., Burnette, B., Fernandez, C., Arina, A., Liang, H., Spiotto, M. T., Posner, M. C., Fu, Y.-X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9915 · Cited by 69
Vijayakumar, G., Palese, P., & Goff, P. H. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.032 · Cited by 69
The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity
Brandmaier, A., & Formenti, S. C. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.005 · Cited by 68
Appleton, E. S., Hassan, J., Hak, C. C. W., Sivamanoharan, N., Wilkins, A. C., Samson, A., Lab), M. O. (., Harrington, K. J., Melcher, A. A., & Wennerberg, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754436 · Cited by 68
Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy
Lu, Y., & Fu, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02334-6 · Cited by 68
Mahmood, J., Shukla, H. D., Soman, S., Samanta, S., Singh, P., Kamlapurkar, S., Saeed, A. M., Amin, N. P., & Vujašković, Ž. (2018) · Cancers · doi:10.3390/cancers10120469 · Cited by 68
Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts
Tseng, C.-W., Trimble, C. L., Zeng, Q., Monie, A., Alvarez, R. D., Huh, W. K., Hoory, T., Wang, M., Hung, C., & Wu, T. ‐. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0596-0 · Cited by 67
The confluence of radiotherapy and immunotherapy
Burnette, B., Fu, Y., & Weichselbaum, R. R. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00143 · Cited by 68
Fiorica, F., Belluomini, L., Stefanelli, A., Santini, A., Urbini, B., Giorgi, C., & Frassoldati, A. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000428 · Cited by 67
Radiation-induced tumor neoantigens: imaging and therapeutic implications.
Corso, C. D., Ali, A. N., & Díaz, R. (2011) · Europe PMC (PubMed Central) · Cited by 67
Local control by radiotherapy: is that all there is?
Formenti, S. C., & Demaria, S. (2008) · Breast Cancer Research · doi:10.1186/bcr2160 · Cited by 67
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma
Almquist, D., Ahn, D. H., & Bekaii‐Saab, T. (2020) · BioDrugs · doi:10.1007/s40259-020-00420-3 · Cited by 66
Li, Q., Xu, L., Zhu, J., Zhong, Y., Yang, J., Wang, J., & Tan, H. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/7530794 · Cited by 66
Molecular determinants of immunogenic cell death elicited by radiation therapy
Galassi, C., Klapp, V., Yamazaki, T., & Galluzzi, L. (2023) · Immunological Reviews · doi:10.1111/imr.13271 · Cited by 67
Immune Priming with Spatially Fractionated Radiation Therapy
Lukas, L., Zhang, H., Cheng, K., & Epstein, A. L. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01473-7 · Cited by 66
An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy
Zhang, H., Liu, L., Yu, D., Kandimalla, E. R., Sun, H. B., Agrawal, S., & Guha, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038111 · Cited by 66
Pathogen-Driven Cancers and Emerging Immune Therapeutic Strategies
Vandeven, N. A., & Nghiem, P. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0179 · Cited by 66
Xǔ, J., Wang, Y., Shi, J., Liu, J., Li, Q., & Chen, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.8946 · Cited by 66
Emerging principles of brain immunology and immune checkpoint blockade in brain metastases
Fares, J., Ulasov, I. V., Timashev, P. S., & Lesniak, M. S. (2021) · Brain · doi:10.1093/brain/awab012 · Cited by 66
Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment
Ishihara, D., Pop, L. M., Takeshima, T., Iyengar, P., & Hannan, R. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1914-6 · Cited by 65
The Optimal Radiation Dose to Induce Robust Systemic Anti-Tumor Immunity
Poleszczuk, J., & Enderling, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113377 · Cited by 65
Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy
Dar, T. B., Henson, R. M., & Shiao, S. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03077 · Cited by 65
Miyauchi, S., Sanders, P. D., Guram, K., Kim, S. S., Paolini, F., Venuti, A., Cohen, E. E. W., Gutkind, J. S., Califano, J. A., & Sharabi, A. B. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1771 · Cited by 64
Nomura, M., Otsuka, A., Kondo, T., Nagai, H., Nonomura, Y., Kaku, Y., Matsumoto, S., & Muto, M. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3444-0 · Cited by 64
Lai, J., Zhu, Y., Ruan, M., Chen, L., & Zhang, Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02857 · Cited by 64
Wang, X., Wang, P., Zhao, Z., Mao, Q., Yu, J., & Li, M. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920926822 · Cited by 64
Faye, M. D., Kassouf, W., Souhami, L., Marcq, G., Cury, F., Niazi, T. M., & Sargos, P. (2020) · World Journal of Urology · doi:10.1007/s00345-020-03440-4 · Cited by 64
Dovedi, S. J., Lipowska‐Bhalla, G., Beers, S. A., Cheadle, E. J., Mu, L., Glennie, M. J., Illidge, T., & Honeychurch, J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0253 · Cited by 63
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Lhuillier, C., Vanpouille-Box, C., Galluzzi, L., Formenti, S. C., & Demaria, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.007 · Cited by 62
Nanomaterials for Combinational Radio–Immuno Oncotherapy
Wang, J., Li, Z., Wang, Z., Yu, Y., Li, D., Li, B., & Ding, J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910676 · Cited by 63
Nakamura, K., Karmokar, A., Farrington, P. M., James, N. H., Ramos‐Montoya, A., Bickerton, S. J., Hughes, G. D., Illidge, T., Cadogan, E. B., Davies, B. R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3701 · Cited by 63
Capitalizing on the Immunogenicity of Dying Tumor Cells
Fonseca, C., & Dranoff, G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2245 · Cited by 63
Patel, K. R., Lawson, D. H., Kudchadkar, R. R., Carthon, B. C., Oliver, D. E., Okwan-Duodu, D. K., Ahmed, R., & Khan, M. K. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov093 · Cited by 62
Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma
Evdokimova, V. E., Gassmann, H., Radvanyi, L. G., & Burdach, S. E. G. (2022) · Cancers · doi:10.3390/cancers15010272 · Cited by 62
Immunosurveillance as a regulator of tissue homeostasis
Senovilla, L., Galluzzi, L., Zitvogel, L., & Kroemer, G. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.06.005 · Cited by 62
Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses
Palena, C., & Schlom, J. (2010) · BioMed Research International · doi:10.1155/2010/380697 · Cited by 62
Self-citationMobilizing the low-avidity T cell repertoire to kill tumors
McMahan, R. H., & Slansky, J. E. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.006 · Cited by 62
Diegeler, S., & Hellweg, C. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00664 · Cited by 62
Immune Checkpoint Inhibitors in the Management of Lung Cancer
Zimmermann, S., Peters, S., Owinokoko, T., & Gadgeel, S. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201319 · Cited by 62
Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Wehrenberg-Klee, E. P., Goyal, L., Dugan, M., Zhu, A. X., & Ganguli, S. (2018) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-018-1993-1 · Cited by 62
Eckert, F., Zwirner, K., Boeke, S., Thorwarth, D., Zips, D., & Huber, S. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00407 · Cited by 62
Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
Nava, S., Lisini, D., Frigerio, S., & Bersano, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212339 · Cited by 63
Deciphering the Biological Effects of Radiotherapy in Cancer Cells
Zhou, L., Zheng, X., Ding, C., Zou, Z., Liang, Y., Zhou, Y., & Li, X. (2022) · Biomolecules · doi:10.3390/biom12091167 · Cited by 61
Targeting Myc-driven stress addiction in colorectal cancer
Saeed, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100963 · Cited by 61
TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models
Young, K. H., Newell, P., Cottam, B., Friedman, D. J., Savage, T., Baird, J. R., Akporiaye, E. T., Gough, M. J., & Crittenden, M. R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0207 · Cited by 61
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Marmorino, F., Boccaccino, A., Germani, M. M., Falcone, A., & Cremolini, C. (2020) · Cancers · doi:10.3390/cancers12082317 · Cited by 56
Tabatabaei, P., Visse, E., Bergström, P., Brännström, T., Siesjö, P., & Bergenheim, A. T. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2271-1 · Cited by 60
Billiard, F., Buard, V., Benderitter, M., & Linard, C. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.12.041 · Cited by 60
Janic, B., Brown, S. L., Neff, R. A., Liu, F., Mao, G., Chen, Y., Jackson, L., Chetty, I. J., Movsas, B., & Wen, N. W. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1861923 · Cited by 59
A Century of Radiation Therapy and Adaptive Immunity
Schaue, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00431 · Cited by 59
Kobayashi, K., Nakachi, I., Naoki, K., Satomi, R., Nakamura, M., Inoue, T., Tateno, H., Sakamaki, F., Sayama, K., Terashima, T., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.01.001 · Cited by 59
Xu, J., Saklatvala, R., Mittal, S., Deshmukh, S., & Procopio, A. (2020) · Advanced Science · doi:10.1002/advs.201903394 · Cited by 56
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Combining radiation and immunotherapy for synergistic antitumor therapy.
Ferrara, T. A., Hodge, J. W., & Gulley, J. L. (2009) · PubMed · Cited by 59
Self-citationTubin, S., Gupta, S., Grusch, M., Popper, H. H., Brčić, L., Ashdown, M. L., Khleif, S. N., Peter‐Vörösmarty, B., Hyden, M., Negrini, S., et al. (2020) · Cancers · doi:10.3390/cancers13010050 · Cited by 59
The Impact of the Myeloid Response to Radiation Therapy
Gough, M. J., Young, K. H., & Crittenden, M. R. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/281958 · Cited by 58
Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell Destruction in Tumors
Wu, C.-Y., Yang, L.-H., Yang, H., Knoff, J. S., Peng, S., Lin, Y.-H., Wang, C., Alvarez, R. D., Pai, S. I., Roden, R. B. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1334 · Cited by 58
Kalina, J. L., Neilson, D. S., Comber, A. P., Rauw, J. M., Alexander, A., Vergidis, J., & Lum, J. J. (2017) · Cancers · doi:10.3390/cancers9020013 · Cited by 58
Checkpoint immunotherapy in head and neck cancers
Zolkind, P., & Uppaluri, R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9694-9 · Cited by 51
Abscopal Effect in Lung Cancer: Three Case Reports and a Concise Review
Garelli, E., Rittmeyer, A., Putora, P. M., Glatzer, M., Dressel, R., & Andreas, S. (2019) · Immunotherapy · doi:10.2217/imt-2019-0105 · Cited by 58
Combination therapy: Future directions of immunotherapy in small cell lung cancer
Huang, W., Chen, J., Xing, R., & Zeng, Y. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100889 · Cited by 58
Clinical impact of HLA class I expression in rectal cancer
Speetjens, F. M., de Bruin, E. C., Morreau, H. M., Zeestraten, E. C. M., Putter, H., van Krieken, J. H., van Buren, M. M., van Velzen, M., Dekker-Ensink, N. G., van de Velde, C. J. �., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0396-y · Cited by 58
Adlard, A. L., Dovedi, S. J., Telfer, B. A., Koga‐Yamakawa, E., Pollard, C., Honeychurch, J., Illidge, T., Murata, M., Robinson, D. T., Jewsbury, P. J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28711 · Cited by 57
CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo
Antonicelli, F. D., Lorin, J., Kurdykowski, S., Gangloff, S. C., Naour, R. L., Sallenave, J., Hornebeck, W., Grange, F., & Bernard, P. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10176.x · Cited by 57
Advances in immunotherapy for cervical cancer
Grau-Béjar, J. F., García-Durán, C., García-Illescas, D., Mirallas, O., & Oaknin, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231163836 · Cited by 56
Qiao, M., Jiang, T., Ren, S., & Zhou, C. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.005 · Cited by 56
Lin, W., Chen, M., Hong, L., Zhao, H., & Chen, Q. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00532 · Cited by 56
Metadata
- Authors
- Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F. A., Spits, H., Schlom, J., van Veelen, P., & Neefjes, J. J.
- Affiliations
- The Netherlands Cancer Institute (NL)
- 2Laboratory of Tumor Immunology and Biology
- National Institutes of Health (US)
- 4Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, and Centre for Medical Systems Biology, 2333 2A Leiden, Netherlands
- Leiden University Medical Center (NL)
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2006-04-24
- Volume
- 203
- Issue
- 5
- Pages
- 1259-1271
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3212727
- OpenAlex
- W2127733313
- Cited by
- 1,737
- References
- 53
- Citations by year
- 2026: 88 · 2025: 116 · 2024: 119 · 2023: 128 · 2022: 149 · 2021: 174 · 2020: 154 · 2019: 118 · 2018: 112 · 2017: 113 · 2016: 78 · 2015: 71 · 2014: 67 · 2013: 62 · 2012: 41
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- radiotherapy, gamma irradiation, MHC class I expression, antigen presentation, protein degradation, mTOR signaling, translation (biology), cytotoxic T lymphocytes, cancer immunotherapy, colon adenocarcinoma
- MeSH terms
- Adenocarcinoma, Animals, Colonic Neoplasms, Dose-Response Relationship, Radiation, Gamma Rays, Humans, Immunotherapy, Mice, Transgenic, Peptides, Protein Kinases, Radiotherapy, T-Lymphocytes, Cytotoxic, Protein Biosynthesis, HLA-A2 Antigen, Gene Expression Regulation, Neoplastic, Antigen Presentation, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.